Ligand

• US 20060063921A1
• Filed: 09/01/2005
• Published: 03/23/2006
• Est. Priority Date: 06/28/2002
• Status: Abandoned Application

• Current Assignee: Domantis Incorporated
• Original Assignee: Domantis Incorporated
• Inventors: Tomlinson, Ian, Moulder, Kevin
• Application Number:
  US11/217,919
• Publication Number:
  US 20060063921A1
• Time in Patent Office: Days
• US Class Current: 530/387.300
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/241 Tumor Necrosis Factors
• CPC Class Codes: C07K 16/2875 against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 against NGF C07K16/22, against TNF C07K16/241
• CPC Class Codes: C07K 16/2878 against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
• CPC Class Codes: C07K 16/40 against enzymes
• CPC Class Codes: C07K 16/42 against immunoglobulins
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/31 multispecific
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/53 Hinge
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/567 Framework region [FR]
• CPC Class Codes: C07K 2317/569 Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C07K 2317/626 Diabody or triabody
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: C07K 2318/20 : Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Abstract

The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.

Claims

1. A human antibody polypeptide monomer which binds to CD40L (gp39).

2. The human antibody polypeptide of claim 1 which dissociates from human CD40L with a Kd in the range of 50 nM to 20 pM, inclusive, as determined by surface plasmon resonance.

3. The human antibody polypeptide of claim 1 wherein said polypeptide comprises a single immunoglobulin variable domain that binds CD40L.

4. The human antibody polypeptide of claim 3 wherein said single immunoglobulin variable domain is a V_H or a V_L domain.

5. An antibody polypeptide of claim 1 which is linked to human serum albumin (HSA).

6. The antibody polypeptide of claim 5 which has an increased in vivo half-life relative to the same polypeptide composition lacking linked HSA.

7. The HSA-linked human antibody polypeptide of claim 5 wherein the tα

-half life of the polypeptide composition is at least 15 minutes.

8. The HSA-linked human antibody polypeptide of claim 5 wherein the tα

-half life of the polypeptide composition is in the range of 15 minutes to 12 hours.

9. The HSA-linked human antibody polypeptide of claim 5 wherein the tβ

-half life of the polypeptide composition is at least 2.5 hours.

10. The HSA-linked human antibody polypeptide of claim 5 wherein the tβ

-half life is in the range of 12 to 48 hours.

11. A composition comprising the antibody polypeptide of claim 1 which is fused to an antibody polypeptide which binds a ligand other than CD40L.

12. The human antibody polypeptide of claim 1 wherein said antibody polypeptide is a single antibody variable domain which lacks a constant region.

13. An antigen-binding polypeptide, said polypeptide comprising a single immunoglobulin variable domain which specifically and monovalently binds CD40L.

14. The polypeptide of claim 13 which consists of a human single immunoglobulin variable domain.

15. The polypeptide of claim 13 which dissociates from human CD40L with a Kd in the range of 50 nM to 20 pM, inclusive, as determined by surface plasmon resonance.

16. The polypeptide of claim 13 wherein said single immunoglobulin variable domain is a human single immunoglobulin variable domain.

17. The polypeptide of claim 13 wherein said single immunoglobulin variable domain is a V_H or a V_L domain.

18. An antibody polypeptide of claim 13 which is linked to human serum albumin (HSA).

19. The antibody polypeptide of claim 18 which has an increased in vivo half-life relative to the same polypeptide composition lacking linked HSA.

20. The HSA-linked human antibody polypeptide of claim 18 wherein the tα

-half life of the polypeptide composition is at least 15 minutes.

21. The HSA-linked human antibody polypeptide of claim 18 wherein the tα

-half life of the polypeptide composition is in the range of 15 minutes to 12 hours.

22. The HSA-linked human antibody polypeptide of claim 18 wherein the tβ

-half life of the polypeptide composition is at least 2.5 hours.

23. The HSA-linked human antibody polypeptide of claim 18 wherein the tβ

-half life is in the range of 12 to 48 hours.

24. The polypeptide of claim 13 wherein said antibody polypeptide is a single antibody variable domain which lacks a constant region.

25. An antibody polypeptide monomer which binds to CD40L, wherein said antibody polypeptide comprises a universal framework.

26. The antibody polypeptide of claim 25 wherein said universal framework comprises a VH framework selected from the group consisting of DP47, DP45 and DP38, and/or the VL framework is DPK9.

27. The antibody polypeptide of claim 25 which comprises a generic ligand binding site.

28. The antibody polypeptide of claim 27 wherein the generic ligand binding site is selected from the group consisting of protein A, protein L and protein G.

29. The antibody polypeptide of claim 25 wherein the antibody polypeptide comprises a variable domain having one or more framework regions comprising an amino acid sequence that is the same as the amino acid sequence of a corresponding framework region encoded by a human germline antibody gene segment, or the amino acid sequences of one or more of said framework regions collectively comprises up to 5 amino acid differences relative to the amino acid sequence of said corresponding framework region encoded by a human germline antibody gene segment.

30. The antibody polypeptide of claim 25 wherein the antibody polypeptide comprises a variable domain, wherein the amino acid sequences of FW1, FW2, FW3 and FW4 are the same as the amino acid sequences of corresponding framework regions encoded by a human germline antibody gene segment, or the antibody sequences of FW1, FW2, FW3 and FW4 collectively contain up to 10 amino acid differences relative to the amino acid sequences of corresponding framework regions encoded by said human germline antibody gene segment.

31. The antibody polypeptide of claim 29 or claim 30 which comprises an antibody variable domain comprising FW1, FW2 and FW3 regions, and the amino acid sequence of said FW1, FW2 anf FW3 are the same as the amino acid sequences of corresponding framework regions encoded by human germline antibody gene segments.

32. The antibody polypeptide of claim 29 or 30 wherein said human germline antibody gene segmentis selected from the group consisting of DP47, DP45, DP38 and DPK9.

33. The antibody polypeptide of claim 25, comprising a V_H domain that is not a camelid immunoglobulin variable domain.

34. The antibody polypeptide of claim 33, comprising a V_H domain that does not contain one or more amino acids that are specific to Camelid immunoglobulin variable domains as compared to human V_H domains.

35. A dual specific ligand comprising a first immunoglobulin single variable domain having a binding specificity to a first antigen and a second single variable domain having a binding activity to a second antigen, wherein the first antigen is CD40L and binding of the second single variable domain to the second antigen acts to increase the half-life of the ligand in vivo.

36. A four chain IgG immunoglobulin comprising a dual specific ligand of claim 35.

37. A four chain IgG immunoglobulin according to claim 36, where in IgG comprises two dual specific ligands, said dual specific ligands being different in their variable domains.

38. The dual specific ligand of claim 35, wherein either

(i) the first and second immunoglobulin variable domains are heavy chain variable domains;

or

(ii) the first and the second immunoglobulin variable domains are light chain variable domains.

39. A dual specific ligand according to claim 38, wherein the ligand is provided as an IgG immunoglobulin comprising four heavy chain single variable domains or four light chain single variable domains.

40. The dual specific ligand of claim 38, wherein the heavy chain domains are Camelid VHH domains.

41. The dual specific ligand according to claim 35, wherein the first and second domains bind independently, such that the dual specific ligand may simultaneously bind both the first and second antigens.

42. A ligand according to any claim 35, wherein the first single variable domain has a dissociation constant (Kd) of 1×

10−

8 M or less for human CD40L, and a Koff rate constant of 1×

10−

3 s−

1 or less, as determined by surface plasmon resonance.

43. A ligand according to claim 35, wherein the second single variable domain is specific for serum albumin (SA) and has a dissociation constant (Kd) of 1 nM to 500 μ

m for SA, as determined by surface plasmon resonance.

44. A ligand according to claim 43, where the second domain binds SA in a standard ligand binding assay with an IC50 of 1 nM to 500 μ

M.

45. A ligand according to claim 35 wherein the second single variable domain is specific for SA, and comprises the amino acid sequence of MSA-16 or a sequence that is at least 80% homologous thereto.

46. A ligand according to claim 35, wherein the second single variable domain is specific for SA, and comprises the amino acid sequence of MSA-26 or a sequence that is at last 80% homologous thereto.

47. The ligand of claim 35, wherein said second antigen which acts to increase the half-life of the ligand in vivo, is a protein found in blood.

55. A ligand according to claim 35, wherein the anti-CD40L variable domain or dAb comprises a universal framework.

56. A ligand according to claim 35, wherein the anti-CD40L variable domain or dAb comprises a VH framework selected from the group consisting of DP47, DP45 and DP38;

or a VL framework which is DPK9.

57. A ligand according to claim 35 which comprises a binding site for a generic ligand.

58. The ligand of claim 57, wherein the generic ligand binding site is selected from the group consisting of protein A, protein L and protein G binding site.

59. A ligand according to claim 35, wherein the anti-CD40L variable domain or dAb comprises one or more framework regions comprising an amino acid sequence that is the same as the amino acid sequence of a corresponding framework region encoded by a human germline antibody gene segment, or the amino acid sequence of one or more of said framework regions collectively comprises up to 5 amino acid differences relative to the amino acid sequence of said corresponding framework region encoded by a human germline antibody gene segment.

60. A ligand according to claim 35, wherein the amino acid sequences of FW1, FW2, FW3 and FW4 of the anti-CD40L variable domain or dAb are the same as the amino acid sequences of corresponding framework regions encoded by a human germline antibody gene segment, or the amino acid sequences of FW1, FW2, FW3 and FW4 collectively contain up to 10 amino acid differences relative to the amino acid sequences of corresponding framework regions encoded by said human germline antibody gene segment.

61. The ligand according to claim 60, wherein the amino acid sequences of said FW1, FW2 and FW3 of the anti-CD40L variable domain or dAb are the same as the amino acid sequences of corresponding framework regions encoded by human germline antibody gene segments.

62. The ligand according to claim 59, wherein said human germline antibody gene segment is selected from the group consisting of DP47, DP45, DP48 and DPK9.

63. The ligand according to claim 60, wherein said human germline antibody gene segment is selected from the group consisting of DP47, DP45, DP48 and DPK9.

64. A method for producing a ligand according to claim 35, comprising a first immunoglobulin single variable domain having a binding specificity for CD40L and a second single immunoglobulin single variable domain having a binding specificity for a protein which increases the half-life of the ligand in vivo, the method comprising the steps of:

selecting a first variable domain by its ability to bind CD40L;

selecting a second variable domain by its ability to bind to said protein;

combining the variable domains; and

selecting the ligand by its ability to bind to CD40L and said protein.

65. A method according to claim 64, wherein said first variable domain is selected for binding to CD40L in absence of a complementary variable domain.

66. Nucleic acid encoding a dual specific ligand according to claim 35.

67. A nucleic acid according to claim 66, comprising the nucleic acid sequence of MSA-16 or a sequence that is at least 80% homologous thereto.

68. A nucleic acid according to claim 66, comprising the nucleic acid sequence of MSA-26 or a sequence that is at least 70% homologous thereto.

69. A vector comprising nucleic acid according to claim 66.

70. A host cell comprising a vector according to claim 69.

71. A pharmaceutical composition comprising a ligand according to claim 35 and a pharmaceutically acceptable excipient, carrier or diluent.

48. The ligand of cliam 35, wherein said second antigen which acts to increase the half-life of the ligand in vivo, is selected from the group consisting of human serum albumin and a transferin receptor.

49. A dual specific ligand comprising an anti-human CD40L dAb and an anti-SA dAb.

50. The ligand according to claim 49, wherein the dAbs are Camelid VHH domains.

51. The ligand according to claim 49, wherein the first single variable domain has a dissociation constant (Kd) of ×

10−

8 M or less for human CD40L, and a Koff rate constant of 1×

10−

3 s−

1 or less, as determined by surface plasmon resonance.

52. The ligand according to claim 49, wherein the second single variable domain is specific for serum albumin (SA) and has a dissociation constant (Kd) of 1 nM to 500 μ

m for SA, as determined by surface plasmon resonance.

53. The ligand according to claim 49, where the second domain binds SA in a standard ligand binding assay with an IC50 of 1 nM to 500 μ

M.

54. The ligand according to claim 49, wherein the anti-SA dAb is an SA-specific domain selected from the group consisting of the amino acid sequence of MSA-16 or a sequence that is at least 80% homologous thereto, an the amino acid sequence of MSA-26 or a sequence that is at least 80% homologous thereto.

94. A pharmaceutical composition comprising a ligand according to claim 51 or 55 and a pharmaceutically acceptable eccipient, carrier or diluent.

72. A dAb monomer specific for CD40L, which monomer has a dissociation constant (Kd) of 1×

10−

8 M or less for human CD40L, and a Koff rate constant of 1×

10−

3 s−

1 or less, as determined by surface plasmon resonance.

76. The dAb monomer of claims 72 or 73, wherein the monomer inhibits binding of CD40 to CD40L with an IC50 of 50 nM or less.

81. The dAb monomer of claim 72 or 73, wherein the dAb is a Camelid VHH domain.

83. Nucleic acid encoding a dAb monomer according to claim 72 or 73.

84. A vector comprising nucleic acid according to claim 83.

85. A host cell comprising a vector according to claim 84.

86. A pharmaceutical composition comprising a dAb according to claim 72 or 73 and a pharmaceutically acceptable ecipient, carrier or diluent.

73. A dAb monomer specific for CD40L with a dissociation constant (Kd) of 1×

10−

7 M or less, as determined by surface plasmon resonance.

74. The dAb monomer of claim 73, wherein the dAb monomer has binding specificity to CD40L with a dissociation constant (Kd) of 1×

10−

8 M or less, as determined by surface plasmon resonance.

75. The dAb monomer of claim 73, wherein dAb monomer has binding specificity to CD40L with a dissociation constant (Kd) of 50 nM to 20 pM, as determined by surface plasmon resonance.

77. The dAb monomer of claim 73, wherein the dAb monomer has binding specificity to CD40L with a Koff rate constant of 1×

10−

3 s−

1 or less, as determined by surface plasmon resonance.

78. The dAb monomer of claim 73, wherein the dAb monomer has binding specificity to CD40L with a Koff rate constant of 1×

10−

4 s−

1 or less, as determined by surface plasmon resonance.

79. The dAb monomer of claim 73, wherein the dAb monomer has binding specificity to CD40L with a Koff rate constant of 1×

10−

5 s−

1 or less, as determined by surface plasmon resonance.

80. The dAb monomer of claim 73, wherein the dAb monomer has binding specificity to CD40L with a Koff rate constant of 1×

10−

6 s−

1 or less, as determined by surface plasmon resonance.

82. The dAb monomer of claim 73, wherein the dAb is a Camelid VHH domain.

87. A dual specific ligand comprising

(i) first and second heavy chain single variable domains, or

(ii) first and second light chain single variable domains,

wherein the first variable domain is an anti-CD40L dAb monomer.

88. The dual specific ligand of claim 87, wherein the anti-CD40L dAb has a dissociation constant (Kd) of 1×

10−

8 M or less for human CD40L, and a Koff rate constant of 1×

10−

3 s−

1 or less, as determined by surface plasmon resonance.

89. The dual specific ligand of claim 87, wherein the anti-CD40L dAb has a dissociation constant (Kd) of 1×

10−

7 M or less, as determined by surface plasmon resonance.

90. The dual specific ligand of claim 87, wherein the second variable domain has binding specificity for an antigen other than CD40L.

91. The dual specific ligand of claim 87, which is a dAb dimer.

92. The ligand of claim 87, wherein the variable domain or dAb is a Camelid VHH domain.

93. A ligand according to claim 87 for use in therapy.